Akero Therapeutics (AKRO) stock was upgraded by Bank of America based on Phase 2 data the company shared for its liver disorder drug, efruxifermin. Read more here.

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) gapped up before the market opened on Tuesday after Morgan ...

Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...

Analyst David Lebowitz of Citi maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a price target of $65.00.Invest ...

We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing ...

Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...